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국문요약 
 
토사자의 항염증 활성 성분 분리 및 유효성분 동시정량 
 
염증 반응은 외부 자극에 대한 생체조직의 방어반응의 일환으로 물리적 
작용이나 유해물질, 화학적 자극, 세균감염 등에 의한 손상을 보상하려는 
기전이다. 하지만 지속적인 염증 반응은 오히려 점막 손상을 유발하고, 그 
결과 암 발생 등 각종 질환을 촉진한다. 다양한 염증 매개물질 중 
일산화질소는 박테리아를 죽이거나 종양을 제거하는 등 중요한 역할을 하지만, 
병인에 의한 과도한 일산화질소 형성은 염증을 유발시키며 조직의 손상, 
유전자 변이 및 신경 손상 등을 일으킨다. 
토사자는 메꽃과(Conbolvulaceas)에 속하며 콩과 식물이나 국화과 식물에 
기생하는 일년생 덩굴식물인 새삼(Cusucta japonica Choisy)과 실새삼(C. australis 
R. Be)의 잘 익은 씨앗을 말린 것이다. 맛이 달고 매우며 주로 간과 신장을 
보호하며 눈을 맑게 해주고 양기를 도우며 신장기능과 뼈를 튼튼하게 해주는 
약재로 알려져 있다. 현재까지는 flavonoid 계열, phenolic 계열과 lignan 계열의 
성분들이 보고되었으나 항염증 활성과 관련된 성분 연구는 아직까지 
체계적으로 이루어진 바 없다. 본 연구에서는 토사자 중에 존재하는 
화합물들을 분리하였으며, 각종 이화학적 성상 및 분광학적 데이터를 
종합하여 이들의 구조를 규명하였다. 이들은 각각 5-hydroxy-6-methyl-2H-
vi 
phran-2-one (1), methyl paraben (2), p-hydroxycinnamate (3), p-coumaric acid (4), 
ferulic acid (5), chlorogenic acid (6), β-sitosterol (7), and daucosterol (8), (-)-asarinin (9), 
4-hydroxysesamin (10), (+)-pinoresinol (11), (+)-epipinoresinol (12), (+)-medioresinol 
(13), kaempferol (14), quercetin (15), isorhamnetin (16), hyperoside (17), rutin (18) 로 
그 구조를 동정하였다. 이들 중 화합물 1 은 천연에서 처음으로 분리, 
보고되는 물질이다. 이 분리된 성분들을 토대로 lipopolysaccharide 를 처리한 
BV-2 세포주를 이용하여 항염증 활성을 평가한 결과, 토사자의 EtOAc 층과 
EtOAc 층에서 분리한 화합물 kaempferol (14), quercetin (15), isorhamnetin (16) 이 
NO 생성을 저해하는 활성을 나타내었다. 또한, 분리한 토사자의 성분으로써 
chlorogenic acid (6), (+)-pinoresinol (11), kaempferol (14), quercetin (15), hyperoside 
(17) 물질들의 함량을 평가하고자 HPLC-DAD 를 이용한 정량법을 확립하고자 
하였으며, 개발된 분석법을 통해 토사자 추출물을 정량 분석하였다. 
 
 
 
 
 
 
 
 
핵심 되는 말: 토사자, 성분연구, 일산화질소, 항염증, 정량법
1 
INTRODUCTION 
The Inflammatory response is the part of protective response of the biological tissue of 
an external stimulus. It is a mechanism of regeneration caused by the damage such as 
toxic substances, physical processes, chemical stimulation, and infection. However, a 
chronic inflammatory response causes various diseases including neurodegenerative 
diseases. Activated microglia also contributes to the initiation and the progression of 
several neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s 
disease (PD), amylotrophic lateral sclerosis and so forth by producing various pro-
inflammatory cytokines. Among various pro-inflammatory cytokines, nitric oxide (NO) 
plays an important role in inflammatory process. The overproduction of NO causes 
damages to the tissue and to the nerve. Thus, regulation of microglia activation and the 
inhibition of NO overproduction could be a potent therapeutic strategy for the treatment 
of various neuroinflammatory diseases.1 
A crude drug prepared from the seeds of Cuscuta chinensis Lam. (Cuscutaceae), is 
commonly used in traditional oriental medicine for the treatment of aching and weakness 
of the loins and knees.2 Many investigations have been established to show various 
biological activities of this plant such as improving sexual function,3 anti-cancer,4 
immunostimulatory5 and antioxidant activities.5 To the best of our knowledge, lignans, 
flavonoids and several phenolic components are known to be its chemical constituents.6 
Based on the previous study of NO inhibitory activity of C. chinensis extract in BV-2 
microglia1, the isolated compounds were evaluated for anti-neuroinflammatory activities 
in lipopolysaccharide (LPS) -stimulated BV-2 microglial cells. 
In this study, one new α-pyrone along with seventeen known compounds were isolated 
from the CHCl3 fraction, EtOAc fraction and n-BuOH fraction of C. chinensis by various 
2 
chromatographic techniques. To quantify these compounds in the extract, a new 
analytical method based on high-performance liquid chromatography with photodiode 
array detector (HPLC-PAD) was developed and validated. Until now, there have been 
only few studies reporting the analysis of chemical constituents of C.chinensis. In the 
previously reported paper, flavonoid (hyperoside, isorhamnetin and kaempferol) in the 
methanol extract of C.chinensis was analyzed using HPLC.7 In the present study, we 
developed and validated a HPLC-DAD method for simultaneous determination of the 
isolated compounds that has been majorly detected, namely chlorogenic acid (6), (+)-
pinoresinol (11), kaempferol (14), quercetin (15), and hyperoside (17) in C. chinensis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
MATERIALS AND METHODS 
1. Plant Material 
 The seeds of C. chinensis were purchased at Kyung-dong herbal market in Seoul, Korea 
in 2014 and a voucher specimen was deposited at the Herbarium of College of Pharmacy, 
Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea. 
 
 
 
 
 
 
 
Figure 1. The seeds of C. chinensis and the pulverized powder 
 
2. Reagents and equipment 
2.1. Reagents for column chromatography 
Packing material of column chromatography 
Silica gel 60 (Kieselgel 60, 70 – 230 mesh and 230 – 400 mesh, Merck, Darmstadt, 
Germany)  
RP Silica gel (YMC RP-18 resins, Fuji Silysia Chemical, Aichi, Japan).  
Plates of thin layer chromatography  
 Silica gel 60F254 (Art. 5715, Merck, Germany)  
 RP-18F254 (Art. 15389, Merck, Germany) 
First grade solvent for extraction, fractionation and isolation: Dae Jung Pure chemi
4 
cal Eng. Co. Ltd., Korea 
HPLC grade solvent: Burdick & Jackson (Muskegon, MI) 
Spray reagent 
Anisaldehyde - H2SO4 
 
2.2. Experimental equipment 
Centrifuge: Effendroff, Germany 
Drying oven: CO-2D-1S, Wooju Sci. Co,. Korea 
Evaporator: EYSLA NE, Japen 
Rotary evaporator: Shimadzu 2102, Japan 
Sonicator: Branson 5200, 5210, UK 
FT-IR: Perkin Elmer 1710 spectrophotometer, USA 
NMR: 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded on an 
Agilent 400-MR NMR spectrometer (Agilent Technologies, Santa Clara, CA). Data 
processing was carried out with the MestReNova 6.0.2 program. 
ESI-MS: Agilent 6550 iFunnel Q-TOF LC/MS system (Agilent Technologies, Santa 
Clara, CA). 
Prep HPLC: Agilent 1260 HPLC system. Column chromatography was performed on 
silica gel (Kieselgel 60, 70 – 230 mesh and 230 – 400 mesh, Merck, Darmstadt, Germany) 
and YMC RP-18 resins (Fuji Silysia Chemical, Aichi, Japan).  
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3. Separation and isolation 
3.1. Extraction and separation 
The dried seeds of C. chinensis (10.0 kg) were extracted with MeOH (3 × 10 L, 50 ℃) 
by sonication for 4 h to yield 349.17 g extract after evaporation of the solvent. This 
extract was suspended in H2O and successively partitioned with CHCl3, EtOAc and n-
BuOH to obtain the CHCl3 (92.36 g), EtOAc (10.55 g), and n-BuOH (36.99 g) extracts 
after removal of the solvents in vacuo. (Scheme. 1) 
 
3.2. Isolation of compounds from the CHCl3 fraction 
The CHCl3 fraction (92.36 g) was subjected to a silica gel column and eluting with a 
gradient of n-hexane – acetone (40 : 1 → 1 : 1, v/v) to obtain four sub-fractions, CC1 
(0.20 g), CC2 (1.15 g), CC3 (0.88 g) and CC4 (0.33 g). The CC1 fraction was 
chromatographed on silica gel column eluting with acetone – water (1.3: 1, v/v) to yield 8 
(3.0 mg). The CC1-2 fraction was chromatographed on HPLC using J’sphere ODS H-80 
250 mm × 20 mm column, eluting with 60% aq. MeCN at the flow rate of 4 mL/min to 
yield 9 (2.9 mg). The CC1-3 fraction was chromatographed on HPLC using J’sphere 
ODS H-80 250 mm × 20 mm column eluting with 60% aq. MeCN at the flow rate of 4 
mL/min to yield 1 (21.2 mg) and 12 (2.0 mg). The CC2 fraction was chromatographed on 
a silica column eluting with CHCl3 – MeOH (5: 1, v/v) to give five smaller fractions, 
CC2-1 (0.01 g), CC2-2 (0.56 g), CC2-3 (0.28 g), CC2-4 (0.02 g), and CC1-5 (0.11 g). 
The CC2-1 fraction was chromatographed on HPLC using J’sphere ODS H-80 250 mm × 
20 mm column, eluting with 62% aq. MeCN at the flow rate of 4 mL/min to yield 10 
(98.3 mg) and 11 (4.9 mg). Compound 7 (5.0 mg) was isolated from CC3 by 
recrystallization (MeOH). The CC4 fraction was chromatographed on a silica column 
6 
eluting with CH2Cl2 – MeOH (15: 1, v/v) to obtain five sub-fraction CC4-1 (0.47 g), 
CC4-2 (0.98 g), CC4-3 (0.658 g), CC4-4 (0.15 g), and CC4-5 (0.05 g). The CC4-2 
fraction was chromatographed on HPLC using J’sphere ODS M-80 250 mm × 20 mm 
column eluting with 50% aq. MeCN at the flow rate of 4 mL/min to yield 2 (21.2 mg), 
and 3 (98.3 mg). (Scheme. 2) 
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Scheme 1. Extraction and fractionation of C. chinensis 
 
 
Scheme 2. Isolation of compounds from the CHCl3 fraction of C. chinensis 
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3.2.1. Compound 1 
Red amorphous powder,  
UV λmax (log ε): 213.6, 274.7  
HR-ESI-MS [M+H]+ 127.0387 [C6H6O3 as 126.0317]  
1H NMR (400MHz, CD3OD): δ (ppm) 7.92 (1H, d, J = 5.4 Hz, H-4), 6.37 (1H, d, J = 
5.4 Hz, H-5), 2.33 (1H, H-9)  
13C NMR (100MHz, CD3OD): δ (ppm) 175.381 (C-2), 156.413 (C-4), 152.336 (C-6), 
144.697 (C-5), 114.529 (C-3), 14.369 (C-9)  
 
3.2.2. Compound 2 
White amorphous powder,  
UV λmax (log ε): 225, 297 
HR-ESI-MS [M+HCOO]- 197.0416 [C8H8O3 as 152.0473]  
1H -NMR (400 MHz, DMSO) δ (ppm): 7.94 (2H, d, J = 8.94 Hz), 6.87 (2H, d, J = 8.94 
Hz), 6.25 (1H), 3.89 (3H, d).  
13C NMR (100 MHz, DMSO) δ (ppm): 122.3(C-1), 132.0 (C-2, 6), 115.4 (C-3, 5), 160.4 
(C-4), 167.5 (C-7), 52.2 (OMe).  
 
3.2.3. Compound 3 
White amorphous powder,  
UV λmax (log ε): 230, 290 
HR-ESI-MS [M+H]+ 166.0578 [C9H8O3 as 164.0473]  
1H -NMR (400 MHz, CD3OD) δ (ppm): δ 7.56 (1H, d, J = 15.8, H-7), 7.42 (2H, d, J = 8.6 
Hz, H-2, 6), 6.77 (2H, d, J = 8.6 Hz, H-3, 5), 6.25 (1H, d, J = 15.8 Hz, H-8) 
9 
13C NMR (100 MHz, CD3OD) δ (ppm): 171.2 (C-9), 161.1 (C-4), 146.6 (C-7), 131.1 (C-2, 
6), 127.3 (C-1), 116.9 (C-3, 5), 115.8 (C-8). 
 
3.2.4. Compound 7 
White amorphous powder,  
1H -NMR (400 MHz, DMSO) δ (ppm): 3.52 (1H, m, H-3), 5.35 (2H, m, H-4), 0.69 (3H, s, 
H-18), 1.01 (3H, s, H-19), 0.92 (3H, d, J = 6.4, H-21), 0.83 (3H, d, J = 6.8, H-26), 0.81 
(3H, d, J = 6.9, H-27), 0.85 (3H, t, J = 7.8, H-29) 
13C NMR (100 MHz, DMSO) δ (ppm): 11.73 (C-29), 12.14 (C-18), 18.63 (C-26), 19.03 
(C-21), 19.39 (C-19),19.82 (C-27), 21.47 (C-11), 23.08 (C-28), 24.31 (C-15), 26.22 (C-
25), 28.18 (C-16), 29.97 (C-23), 31.73 (C-2), 31.95 (C-8), 32.03 (C-7), 34.89 (C-22), 
36.11 (C-20), 36.69 (C-10), 37.24 (C-1), 40.27 (C-12), 42.32 (C-4), 42.61 (C-13), 50.33 
(C-24), 50.92 (C-9), 56.11 (C-17), 57.02 (C-14) 
 
3.2.5. Compound 8 
White amorphous powder,  
1H -NMR (400 MHz, DMSO) δ (ppm): 0.70 (1H, H-18), 0.83 (1H, d, J = 6.9 Hz, H- 
27), 0.85 (1H, t, J = 7.4 Hz, H-29), 0.93 (1H, m, H-24), 0.94 (1H, d, J = 5.3 Hz, H-26), 
0.95 (1H, d, J = 5.1 Hz, H-21), 0.96 (1H, m, H-9), 1.02 (1H, m, H-11), 1.03 (1H, H- 
19), 3.23 (1H, t, J = 7.9 Hz, H-2'), 3.29 (1H, m, H-5'), 3.42 (1H, t, J = 7.9 Hz, H-3'), 3.42 
(1H, m, H-4'), 3.59 (1H, m, H-3), 3.75 (1H, dd, J = 10.0; 5.0 Hz, H-6'), 3.84 (1H, d, J = 
10.0 Hz, H-6'a), 4.41 (1H, d, J = 7.9 Hz, H-1'), 5.37 (1H, d, J = 5.0 Hz, H-6) 
13C NMR (100 MHz, DMSO) δ (ppm): 12.1 (C-18), 12.3 (C-29), 18.9 (C-21), 19.2 (C-27), 
19.5 (C-19), 19.9 (C-26), 21.2 (C-11), 23.4 (C-28), 24.6 (C-15), 26.4 (C-23), 28.6 (C-16), 
10 
29.5 (C-25), 29.9 (C-2), 32.3 (C-7), 32.3 (C-8), 34.3 (C-22), 36.5 (C-20), 37.1 (C-10), 
37.6 (C-1), 39.0 (C-4), 40.8 (C-12), 42.7 (C-13), 46.2 (C-24), 50.6 (C-9), 56.4 (C-17), 
57.2 (C-14), 62.2 (C-6'), 70.7 (C-4'), 74.0 (C-2'), 76.3 (C-5'), 76.9 (C-3'), 79.5 (C-3), 
101.5 (C-1'), 122.4 (C-6), 140.7 (C-5) 
 
3.2.6. Compound 9 
White amorphous powder,  
UV λmax (log ε): 231, 280 
HR-ESI-MS [M+H]+ 356.1204 [C20H18O6  as 354.1103]  
 1H -NMR (400 MHz CD3OD) δ (ppm): 2.88 (1H, m, H-1), 3.31 (2H, m, H-5, H-4β), 
3.83 (2H, m, H-8α, H-4α), 4.10 (1H, d, J = 8 Hz, H-8β), 4.41 (1H, d, J = 8 Hz, H-2), 4.83 
(1H, d, J = 4 Hz, H-6), 5.95 (4H, s, 2 x OCH2O), 6.77-6.86 (6H, m, H-2', H-2'', H-5', H-5'', 
H-6', H-6'') 
 13C-NMR (100 MHz, CD3OD) δ (ppm): see Table 2 
 
3.2.7. Compound 10 
Brown amorphous powder,  
UV λmax (log ε): 232, 281 
HR-ESI-MS [M+HCOO]- 399.0475 [C20H18O7 as 370.35272]  
 1H -NMR (400 MHz, CD3OD) δ (ppm): 3.55 (2H, m, 9-H), 2.90 (H, m, H-8), 4.8 (H, m, 
7-H), 6.77 (H, m, 2-H), 6.80 (H, m, 3-H), 6.87 (H, m, 6-H), 4.0 (2H, m, H-9'a), 4.20 (2H, 
m, H-9'b), 3.20 (H, m, H-8'), 4.90 (H, m, 7'-H), 6.89 (H, m, 2'-H), 6.80 (H, m, 3'-H), 7.03 
(H, m, 6'-H), 5.90 (2 x OCH2O) 
 13C-NMR (100 MHz, CD3OD) δ (ppm): see Table 2 
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3.2.8. Compound 11 
Brown amorphous powder,  
UV λmax (log ε): 230, 281 
HR-ESI-MS [M+H]+ 360.1426 [C20H22O6 as 358.1416] 
1H -NMR (400 MHz, CD3OD) δ (ppm): 3.0-32 (2H, m, C1,5H), 3.87 (6H, s, 2 x OCH3), 
3.64-4.36 (4H, m, C4, 8-H), 4,73 (2H, d, J = 5 Hz, C2, 6-H), 6.80-6.92 (6H, m, aromatic). 
13C-NMR (100 MHz, CD3OD) δ (ppm): see Table 2 
 
3.2.9. Compound 12 
Brown amorphous powder,  
UV λmax (log ε): 232, 281 
HR-ESI-MS [M+H]+ 360.1426 [C21H24O7 as 358.1416]  
1H -NMR (400 MHz, CD3OD) δ (ppm): 3.76 (3H, s, OMe), 4.28 (1H, d, J = 7.0, H-6), 
4.74 (1H, d, J = 5.2, H-2), 6.77-6.88 (6H, m, aromatic). 
13C-NMR (100 MHz, CD3OD) δ (ppm): see Table 2 
 
3.2.10. Compound 13 
Brown amorphous powder,  
UV λmax (log ε): 266, 367 
HR-ESI-MS [M+H]+ 389.1552 [C21H24O7 as 388.41106] 
1H -NMR (400 MHz, CD3OD) δ (ppm): 2.92-3.16 (2H, m, 5-H), 3.76 (9H, s, 3 x OCH3), 
3.80-4.40 (4H, m, 8-H), 4.52-4.68 (2H, m, H-6), 6.52-6.92 (5H, m, aromatic). 
13C-NMR (100 MHz, CD3OD) δ (ppm): see Table 2 
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3.3. Isolation of compounds from the EtOAc fraction 
The EtOAc fraction (10.55 g) was chromatographed on an YMC RP-18 column 
eluting with a gradient of acetone – water (10 : 1 → 1 : 1, v/v) to obtain four sub-fractions, 
CC-E1 (3.23 g), CC-E2 (0.03 g), CC-E3 (1.03 g), and CC-E4 (0.83 g). Compound 14 
(869 mg) was isolated form CC-E3 by recrystallization (MeOH). Compound 15 (3mg) 
and 16 (2mg) were purified from CC-E2A by HPLC using J’sphere ODS H-80 250 mm × 
20 mm column eluting with 40% aq. MeCN. Compound 6 (6 mg) was isolated form CC-
E2B by recrystallization (MeOH). 
 
3.3.1. Compound 6 
Brown amorphous powder,  
UV λmax (log ε): 242, 298, 325 
HR-ESI-MS [M+Na]+ 377.0846 [C15H10O6 as 354.0951] 
1H -NMR (400 MHz, DMSO) δ (ppm): 7.45 (1H, d, J = 16.2 Hz, H-7′), 6.22 (1H, d, J = 
15.6 Hz, H-8′), 7.05 (1H, brs, H-2′), 6.98 (1H, d, J = 8.4 Hz, H-6′), 6.75 (1H, d, J =7.8 
Hz, H-5′), 5.14 (1H, m, H-3), 4.64 (1H, m, H-4), 3.91 (1H, m, H-5), 1.97–1.67 (2H, m, 
H-2,6). 
13C NMR (100 MHz, DMSO) δ (ppm): 174.83 (C-7), 165.62 (C-9),148.23 (C-4), 145.45 
(C-3), 144.48 (C-7), 125.48 (C-1), 121.26 (C-6), 115.63 (C-5), 114.66 (C-2), 114.18 (C-
8), 73.35 (C-1), 70.77 (C-3), 70.24 (C-4), 67.95 (C-5), 37.09 (C-6), 36.01(C-2). 
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3.3.2. Compound 14 
Yellow amorphous powder,  
UV λmax (log ε): 231, 309, 356 
HR-ESI-MS [M+H]+ 287.0551 [C15H10O6 as 286.0477]  
1H -NMR (400 MHz, DMSO) δ (ppm): 6.45 (H, s, H-6), 6.25 (H, s, H-8), 8.02 (H, d, J = 
8.76 Hz, H-20), 6.93 (H, d, J = 8.76 Hz, H-3′), 6.93 (H, d, J = 8.76 Hz, H-5′), 8.02 (H, d, 
J = 8.76 Hz, H-6′). 
13C NMR (100 MHz, DMSO) δ (ppm): 146.9 (C-2), 135.5 (C-3), 180.0 (C-4), 102.5 (C-
10), 160.7 (C-5), 93.1 (CH-6), 163.9 (C-7), 98.2 (C-8), 156.0 (C-9), 121.4 (C-1′), 129.5 
(C-2′), 115.5 (C-3′), 159.5 (C-4′), 115.5 (C-5′), 129.5 (C-6′). 
 
3.3.3. Compound 15 
Yellow amorphous powder,  
UV λmax (log ε): 231, 309, 356 
HR-ESI-MS [M+H]+ 304.0531 [C6H6O3 as 302.0427]  
1H -NMR (400 MHz, DMSO) δ (ppm): 6.17 (1H, d, J = 2.0 Hz, H-6), 6.37 (1H, d, J = 2.0 
Hz, H-8), 6.87 (1H, d, J = 8.0 Hz, H-5′), 7.62(1H, dd, J = 2.0, 7.5 Hz, H-6′), 7.73 (1H, d, 
J = 2.0 Hz, H-2′). 
13C NMR (100 MHz, DMSO) δ (ppm): 147.1 (C-2), 136.0 (C-3), 176.0 (C-4), 103.4 (C-
10), 160.9 (C-5), 98.7 (C-6), 164.2 (C-7), 93.9 (C-8), 160.9 (C-9), 122.4 (C-1′), 115.5 (C-
2′), 145.3 (C-3′), 147.9 (C-4′), 116.0 (C-5′), 120.0 (C-6′). 
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3.3.4. Compound 16 
Yellow amorphous powder,  
UV λmax (log ε): 266, 322 
HR-ESI-MS [M+HCOO]- 361.0549 [C16H12O7 as 316.0583]  
1H -NMR (400 MHz, DMSO) δ (ppm): 3.84 (3H, s, OCH3), 6.20 (1H, d, H-6), 6.48 (1H, 
d, H-8), 6.94 (1H, d, H-5′), 7.69 (1H, m, H-6′), 7.75 (1H, d, H-2′), 9.40 (1H, s, OH), 9.73 
(1H, s, OH), 10.76 (1H, s, OH), 12.46 (1H, s, OH). 
13C NMR (100 MHz, DMSO) δ (ppm): 148.61 (C-2), 135.62 (C-3), 175.72 (C-4), 156.05 
(C-5), 98.11 (C-6), 163.71 (C-7), 93.53 (C-8), 160.32 (C-9), 102.91 (C-10),121.84(C-1′), 
111.56 (C-2′), 146.43 (C-3′), 147.21 (C-4′), 115.33 (C-5′), 121.64 (C-6′), 55.63 (OCH3). 
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3.4. Isolation of compounds from the n-BuOH fraction 
The n-BuOH fraction (36.99 g) was chromatographed on a silica gel column eluting 
with a mixture of CHCl3 – MeOH = 20:1, 10:1, 5:1, 2.5:1, 1: 1 (v/v) to yield six fractions, 
CC-B1 (3.53 g), CC-B2 (2.85 g), CC-B3 (4.09 g), CC-B4 (5.96 g), CC-B5 (7.7 g) and 
CC-B6 (3.8 g). The CC-B1 fraction was chromatographed on a silica column eluting with 
CHCl3– MeOH (20: 1, v/v) to give four smaller fractions CC-B1A (0.0926 g), CC-B1B 
(0.33 g), CC-B1C (0.04 g) and CC-B1D (1.5 g). The CC-B1A fraction was 
chromatographed on HPLC using J’sphere ODS H-80 250 mm × 20 mm column eluting 
with 30% aq. MeCN at the flow rate of 4 mL/min to yield 18 (2.1mg). Compound 8 (653 
mg) was isolated from CC-B1A by recrystallization (MeOH). The CC-B2 fraction was 
chromatographed on a silica column eluting with CHCl3 – MeOH (8: 1, v/v) to give 
several smaller fractions. Compound 17 (653 mg) was isolated from CC-B2C by 
recrystallization (MeOH). The CC-B3 fraction in HPLC using J’sphere ODS H-80 250 
mm × 20 mm column eluting with 50% aq. MeCN at the flow rate of 4 mL/min to yield 4 
(2.3mg) and 5 (3.6mg).  
 
3.4.1. Compound 4 
White amorphous powder,  
UV λmax (log ε): 235, 294 
HR-EIS-MS [M-H]- 178.0590 [C10H10O3 as 178.0630]  
1H -NMR (400 MHz, DMSO) δ (ppm): 9.01 (1H, OH), 7.71 (1H, d, J =16.2 Hz, H-7), 
7.65 (2H, d, J = 8.4 Hz, H-2, 6), 6.99 (2H, d, J= 8.4 Hz, H-3, 5), 6.45 (1H, d, J= 16.2 Hz, 
H-8), 3.81(3H, COOCH3). 
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13C NMR (100 MHz, DMSO) δ (ppm): 167.08 (C-9), 159.76 (C-4), 144.58 (C-7), 130.13 
(C-2, 6), 126.16 (C-1), 115.85 (C-3 and C-5), 114.47 (C-8), 50.67 (COOCH3). 
 
3.4.2. Compound 5 
White amorphous powder  
UV λmax (log ε): 225, 297 
HR-ESI-MS [M-H]- 193.0536 [C8H8O3 as 194.0579]  
1H NMR (400 MHz, CD3OD) δ (ppm): 3.98 (3H, s, (1H, dd, J = 8 and 2 Hz, H-5), 6.34 
(1H, d, J =15 Hz, H-3′), 6.97(1H, d, J = 9 Hz, H-6), 7.14 (1H, dd, J = 8 and 2 Hz, H-5), 
7.09 (1H, d, J = 2 Hz, H-3), 7.75 (1H, d, J = 15 Hz, H-1′).  
13C NMR (100 MHz, CD3OD) δ (ppm): 55.98 (C-4′), 109.48 (C-5), 114.39 (C-2), 114.78 
(C-2′), 23.57 (C-3), 126.68 (C-4), 146.81 (C-1′), 147.05 (C-6), 147.05 (C-6), 148.37 (C-
1), 171.36 (C-3′). 
 
3.4.4. Compound 17 
Yellow amorphous powder  
UV λmax (log ε): 231, 309, 356 
HR-ESI-MS [M+Na]+ 487.0847 [C21H20O12 as 464.0955]  
1H NMR (400 MHz, DMSO) δ (ppm): 12.63 (5-OH, s), 6.19 (1H, brs, H-6), 6.40 (1H, brs, 
H-8), 7.57(1H, brs, H-2′), 6.81 (1H, d, J = 7.8 Hz, H-5′), 7.67 (1H, d, J = 9 Hz, H-6′), 
5.38 (1H, d, J = 7.8 Hz, H-1′′), 0.86 (3H, d, J = 6.6 Hz, H-6′′).  
13C NMR (100 MHz, DMSO) δ (ppm): 159.3 (C-2), 136.6 (C-3), 180.3 (C-4), 106.4 (C-
10), 163.8 (C-5), 100.7 (CH-6), 167.0 (C-7), 95.5 (C-8), 159.6 (C-9), 123.7 (C-1′), 116.9 
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(C-2′), 146.6 (C-3′), 150.8 (C-4′), 118.6 (CH-5′), 123.7 (CH-6′), 106.2 (C-1′′), 73.9 (C-2′′), 
75.9 (C-3′′), 70.8 (C-4′′), 78.0 (C-5′′), 62.8 (C-6′′).  
 
3.4.5. Compound 18 
Yellow amorphous powder  
UV λmax (log ε): 263, 364 
HR-ESI-MS [M+H]+ 611.1609 [C27H30O16 as 610.1534] 
1H NMR (400 MHz, DMSO) δ (ppm): 1.34 (3H, br s, CH3), 3.80–4.10 (10 carbohydrate 
protons), 5.14 (1H, s, H-1′′′′), 5.78(1H, d, J = 7.5, H-1′′), 6.53 (2H, br s, H-6, 8), 7.17 (1H, 
d, J = 8.5, H-5′), 7.90 (1H, dd, J = 8.5, H-6′), 8.13(1H, br s, H-2′).  
13C NMR (100 MHz, DMSO) δ (ppm): 17.81 (C-6′′′), 68.31 (C-6′′), 69.84 (C-5′′′), 71.34 
(C-2′′′), 72.23 (C-3′′′), 73.83 (C-4′′), 74.34 (C-4′′′), 75.68 (C-2′′), 77.25 (C-5′′), 78.14 (C-
3′′), 94.63 (C-8), 99.82 (C-6), 102.08 (C-1′′′), 104.51 (C-1′′), 105.67 (C-10), 115.47 (C-2′), 
116.67 (C-5′), 123.27 (C-6′), 123.75 (C-1′), 135.77 (C-3), 145.61 (C-3′), 149.92 (C-4′), 
159.05 (C-9), 159.21 (C-2), 163.41 (C-5), 165.97 (C-7), 179.32 (C-4). 
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Scheme 3. Isolation of compounds from the EtOAc fraction of C. chinensis 
 
Scheme 4. Isolation of compounds from n-BuOH fraction of C.chinensis 
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4. Evaluation of anti-inflammatory activities in LPS-stimulated 
BV-2 microglial cells 
4.1. Cell culture 
BV-2 cells with the phenotypic and functional characteristics of reactive microglial 
cells were originally developed by Dr. V. Vocchini, at the University of Perugia (Italy). 
Cells were grown in DMEM, and supplemented with 5% FBS and 1% penicillin 
streptomycin. The cells were cultured in a humidified atmosphere of 5% CO2 at 37°C. 
 
4.2. Measurement of NO production 
 In order to measure NO production, BV-2 cells were plated into a 96-well plate (3.0 x 
104 cells / well) and treated with LPS in the presence or absence of samples for 24 h. 
Nitrite, a soluble oxidation product of NO, in the culture media was detected using the 
Griess reagents.8 The supernatant (50μl) was harvested and mixed with an equal volume 
of Griess reagent (1% sulfanilamide and 0.1% N-1-napthylethylenediamine 
dihydrochloride in 5% phosphoric acid). After 10 min, the absorbance at 570 nm was 
measured using a microplate reader. Sodium nitrite was used as a standard to calculate 
NO2 concentration. 
 
4.3. Cell viability 
Cell viability was measured using a MTT [3-(4, 5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay. After the medium was removed, cells were 
incubated with MTT (0.1 mg/ml) for 1 h at 37°C. Absorbance was measured at 570 nm 
using a micro plate reader (Molecular Devices E09090; San Francisco, CA, USA).  
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5. Analysis of C. chinensis using HPLC-DAD 
5.1. Preparation of standard solution  
Each stock standard solution for chlorogenic acid (0.4 mg/mL) and (+)-pinoresinol (0.4 
mg/mL) was prepared in 100% methanol, respectively. The other three compounds, 
kaempferol (1.0 mg/mL), hyperoside (4.0 mg/mL), and quercetin (0.4 mg/mL) were 
dissolved in 50% methanol and prepared as stock standard solutions, respectively. The 
appropriate amount of every standard solution was mixed and diluted with methanol 
before use. 
 
5.2. Preparation of sample solution 
The total methanol extract of C. chinensis was dissolved in 100% methanol at the 
concentration of 50 mg/ml. Then, it was filtered by a 0.2 μm Nylon syringe filter (Thermo 
Scientific, Germany) before HPLC analysis.  
 
5.3. HPLC-DAD condition 
The quantitative determination of the isolated compounds was performed on an 
Agilent 1290 Infinity liquid chromatography system equipped with the G4220A Quad 
pump solvent delivery system and UV–VIS photodiode array detector G4212A (Agilent 
Technologies, Inc., Santa Clara, CA). HPLC-DAD analysis was carried out at 30 °C on 
Shiseido hydrosphere C18 column (5 μm; 250 × 4.6 mm). A binary gradient elution 
system composed of MeCN (phase A) and 0.1% phosphoric acid in water ((v/v), phase B) 
was applied to the analysis with the gradient elution as follows: 0-15% (B) in 0-45 min, 
15-30% (B) in 45-66 min, 30-36.2% (B) in 66-80 min, 36.2-48.2% (B). The wavelength 
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was set at 230 nm and the mobile flow rate was at 0.5 mL/min. Aliquots of 3 μL were 
injected into the HPLC. 
 
5.4. Method validation 
The HPLC method was validated in terms of specificity, linearity, precision, accuracy 
and stability according to International Conference on Harmonization guidelines. 
Specificity was determined by the calculation of peak purity facilitated by DAD and its 
corresponding computer software. Each retention time and UV spectrum were verified 
with those of each standard compound. To calculate the calibration curves of the five 
compounds, a standard solution for each compound was prepared and diluted to the 
appropriate concentrations. Five different concentrations of each compound were 
analyzed in triplicate. Precision was assayed at five different concentrations in duplicate 
on the same day. The results were expressed by the relative standard deviation (RSD). 
The accuracy was determined by the method of standard addition. The diluted sample 
solution of 100% methanol extract of C. chinensis (50 mg/mL) was spiked with the 
mixture of standard compounds in the ratios of 1:1, 1:2, and 2:1.  
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RESULTS 
1. Elucidation of chemical structure of compounds isolated from the 
seed of C. chinensis extract 
1.1.1. Compound 1  
Compound 1 was obtained as red amorphous power. The molecular formula was 
determined as C6H6O3 on the basis of HR-ESI-MS [M+H]
+ ion at m/z 127.0387 (calcd for 
C6H7O3, 127.0317). The IR spectrum of the titled compound showed strong absorptions at 
3247.14 and 1609.02 cm-1 for OH and C=O respectively. The hydrogen bonds and 
resonance resulted in the lowering of the carbonyl frequency. Other peaks at 3060.63, 
172.59, 1559.30, 1458.96, 1368.89, 1254.12, 1195.88, 1121.83, 1074.56, 1022.26, 916.88, 
838.758, 685.18 cm-1 show the stretching and bending frequency of C-H, C=C, and C-O. 
The UV spectrum exhibited absorptions at 213.6 and 274.7 nm.  
The 1H -NMR (CD3OD 400 MHz) showed one methyl resonance at δH 2.33 (3H, s) and 
two methine resonances at δH 6.37 (d, J = 5.2 Hz) and δH 7.92 (d, J = 5.2 Hz). The same 
J-value indicated that these protons are located next to each other. The 13C and DEPT 
NMR spectra (Figure 1) revealed the presence of one methyl carbon, two methine 
carbons, and three quaternary carbons. The HSQC spectrum showed H-5 (δH 6.37 (d, J = 
5.2 Hz)) and H-4 (δH 7.92 (d, J = 5.2 Hz)) correlated to C-3 (δC 114.52) and C-4 (δC 
156.41), respectively. The correlations between H-3 (δH 6.37) and C-2 (δC 175.38) and 
quaternary C-5 (δC 144.69) were observed in the HMBC spectrum. In general, 
13C NMR 
spectrum of C=O is located at the chemical shift of δC 170-210 ppm. Thus, C-2 signal had 
to be a carbonyl group. In addition, C-5 must be attached to a hydroxyl group in order to 
be δC 144.69. The HMBC correlation between H-4 (δH 7.92) and quaternary C-6 (δC 
23 
152.33) and between H-9 (δH 2.33) and C-6 (δC 152.33) suggested that the methyl group 
was attached at C-6. Compared to quaternary carbon without oxygen, the chemical shift 
of C-6 located at downfield and the chemical shift of C-2 was moved to upfield compared 
to those of no esterized carbonyl group, which can be deduced that C-2 and C-6 were 
connected by oxygen. Based on the evidence above, compound 1 was determined as 5-
hydroxy-6-methyl-2H-pyran-2-one and was isolated for the first time from the nature. 
 
1.1.2. Compound 2 
Compound 2 was obtained as brown amorphous power. The molecular formula was 
established to be C8H8O3 on the basis of HR-ESI-MS [M+H]
+ at m/z 197.0416.  
 The 1H NMR spectrum at δH 7.46 (d, J = 8.5 Hz) and 6.80 (d, J = 8.5 Hz), indicating 
the presence of a 1,4-disubsituted symmetrical aromatic ring. The 13C NMR spectrum of 
compound 2 exhibited the aromatic ring (δC 122.7 (C-1), δC 115.8 (C-3, 5), δC 131.3 (C-2, 
6)) and hydroxyl (δC 160.4 (C-4)), carbonyl (δC 167.5 (C-7)) and ether group (δC 52.2 (C-
8)) in different magnetic environments. Based on the evidence above, compound 2 was 
determined as methyl paraben.9 
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Figure 2. 1H –NMR and 13C –NMR spectra of compound 1 
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J= 5.4 Hz J= 5.4 Hz 
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Figure 3. DEPT NMR and HSQC NMR spectra of compound 1 
 
 
26 
 
 
Figure 4. HMBC spectrum of compound 1 
 
Figure 5. COSY spectrum of compound 1 
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Figure 6. UV spectrum of compound 1 
 
Figure 7. IR spectrum of compound 1 
 
Figure 8. HR-ESI-MS spectrum of compound 1 
(M+H)+,127.0387 
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Figure 9. 1H –NMR and 13C –NMR spectra of compound 2 
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1.1.3. Compound 3 
Compound 3 was obtained as brown amorphous power. The molecular formula was 
established to be C9H8O3 on the basis of HR-ESI-MS [M+H]
+ at m/z 166.0578. The 1H 
NMR spectrum at δ 7.36 (d, J = 8.3 Hz) and 6.71 (d, J = 8.3 Hz), indicating the presence 
of a 1,4-disubsituted symmetrical aromatic ring. Two coupling olefinic protons at δ 7.52 
(d, J = 16.0 Hz) and 6.23 (d, J = 16.0 Hz) suggested a Z-form double bond. Moreover, the 
quaternary carbon at δ 177.8 suggested the presence of a carboxyl group. Based on the 
evidence above, compound 2 was determined as (Z)-4-coumaric acid.10 
 
1.1.4. Compound 4  
Compound 4 was obtained as brown amorphous power. The molecular formula was 
established to be C10H10O3 on the basis of HR-ESI-MS [M-H]
- at m/z 178.0590. The 13C 
NMR spectral data of compound 4 were almost the same as those of compound 3, except 
for the additional signal of one methoxy group, which is identical with that of methyl 
ester. Based on the evidence above, compound 4 was determined as 4-coumaric acid 
methyl ester.11 
  
1.1.5. Compound 5  
Compound 5 was obtained as brown amorphous power. The molecular formula was 
established to be C8H8O3 on the basis of HR-ESI-MS [M+HCOO]
- at m/z 197.0416. The 
13C NMR spectral data of compound 3 were almost the same as those of compound 5, 
except for the additional signal of one methoxy group. In contrast to compound 4, since 
methoxy group carbon attached to a benzene ring carbon was moved the chemical shifts. 
Based on the evidence above, compound 5 was determined as ferulic acid.12 
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Figure 10. 1H –NMR and 13C –NMR spectra of compound 3 
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Figure 11. 1H –NMR and 13C –NMR spectra of compound 4 
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Figure 12. 1H –NMR and 13C –NMR spectra of compound 5 
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1.1.6. Compound 6  
Compound 6 was obtained as brown amorphous power. The molecular formula was 
established to be C16H18O9 on the basis of HR-ESI-MS [M+H]
+ at m/z 358.1109. The 1H -
NMR spectrum at δ 7.56 (d, J = 15.9 Hz), 7.18 (d, J = 2.0 Hz), 7.13 (dd, J = 8.2, 2.0 Hz), 
6.91 (d, J = 8.1 Hz) and 6.29 (d, J = 15.9 Hz) suggested the presence of a caffeoyl moiety. 
The 1H -NMR signals at δ 5.21, 4.07, 3.71, 2.65, 2.10, 2.07 and 1.93 together with the 13C 
-NMR signals at δ 176.8, 74.0, 73.3, 71.9, 69.2, 39.2 and 38.3 could be assigned as a 
quinic acid moiety. Characteristic signals displayed 5 carbons attached to hydroxyl group 
(C-1, δ 73.491, C-3, δ 68.061, C-4, δ 70.937, C-3', δ 145.0318, and C-4', δ148.391) and 
another carbon attached to a carboxylic acid group (C-7, δ 176.8). Based on the evidence 
above, compound 6 was determined as chlorogenic acid.13  
 
1.1.7. Compound 7  
Compound 7 was obtained as white amorphous power. The compound 7 was showed the 
red color indicating itself as sterol in thin layer chromatography (TLC). Compared to 
standard compound, a spot of the standard had the same Rf value. It was used to estimate 
the presence of β-sitosterol. Based on the evidence above, compound 6 was determined as 
β-sitosterol. 14 
 
1.1.8. Compound 8  
The 13C NMR spectral data of compound 7 were almost the same as those of compound 
8, except for the additional signals of sugar moiety identical with that of glucoside. Based 
on the evidence above, compound 8 was determined as daucosterol.14 
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Figure 13. 1H –NMR and 13C –NMR spectra of compound 6 
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Figure 14. 1H –NMR and 13C –NMR spectra of compound 7 
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Figure 15. 1H –NMR and 13C –NMR spectra of compound 8 
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1.1.9. Compound 9   
Compound 9 was obtained as brown amorphous power. The molecular formula was 
established to be C20H18O6 on the basis of HR-ESI-MS ([M+H]
+ at m/z 356.1204). The 1H 
NMR spectrum of compound 9 exhibited the aromatic methylenedioxy and eight 
additional protons in more than four different magnetic environments, clearly consistent 
with an axial-equatorial configuration for the aryl groups. The 13C NMR spectrum 
showed 16 signals, including 2 carbons attached with C-1, C-1″ (δ 135.58 and δ 135.62). 
The chemical shifts of carbons in the literature were compared with those spectral data. 
As a result, compound 9 was identified as (-)-asarinin.15 
 
1.1.10. Compound 10  
Compound 10 was obtained as brown amorphous power. The molecular formula was 
established to be C20H18O7 on the basis of HR-ESI-MS ([M+HCOO]
- at m/z 399.0475). 
The 13C NMR spectral data of compound 9 were almost the same as those of compound 
10 except for the additional signal of one hydroxyl group. Based on the evidence above, 
compound 10 was determined as 4-hydroxysesamine.16 
 
1.1.11. Compound 11  
Compound 11 was obtained as brown amorphous power. The molecular formula was 
established to be C20H22O6 on the basis of HR-ESI-MS ([M+H]
+ at m/z 360.1426). The 
1H NMR spectrum of compound 11 exhibited a symmetric structure which showed the 
presence of two overlapping aromatic methoxy group at δH 3.90 ppm; two equivalent 
aromatic protons at δH 6.77 (d, J = 8.6 Hz), δH 6.73 (d, J = 8.1 Hz) and δH 6.91 (s). The 
other protons (δH 3.090 – 4.820 ppm) indicated the signals from a bis-tetrahydrofuran ring. 
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Thus, the characteristic signals displayed two benzyl methane protons at δ 4.66 (d, J = 3.9 
Hz), two hydroxyl groups as broad singlet at δ 5.6 ppm. The 13C NMR spectrum indicated 
that it is a tetrahydrofuran lignan derivative of 2,6-diaryl-3,7-dioxabicyclo[3.3.0]octane 
(furofuran) type with the presence of two guaiacyl moieties as deduced from the signals 
at  δc 132.6 (C-1′ and 1″), 110.0 (C-2′ and 2″), 148.2 (C-3′ and 3″), 146.5 (C-4′ and 4″), 
115.5 (C-5′ and 5″), 119.0 (C-6′ and 6″) and 56.1 (2 × OMe) with δH 6.71-6.83 (6H, m, 
aromatic H) and 3.78 (6H, s, 2 × OMe). Based on the evidence above, compound 11 was 
confirmed as symmetrical furanofuran-ligan, (+)-pinoresinol.17 
 
1.1.12. Compound 12  
Compound 12 was obtained as brown amorphous power. The molecular formula was 
established to be C21H24O7 on the basis of HR-ESI-MS ([M+H]
+ at m/z 360.1426). The 1H 
and 13C NMR spectrum of 12 were very similar to those of 11, but each signal appeared 
as paired signals, suggesting that 12 might be an unsymmetrical isomer of 11. Based on 
the evidence above, compound 12 was determined as epipinoresinol. 18 
 
1.1.13. Compound 13  
Compound 13 was obtained as brown amorphous power. The molecular formula was 
established to be C21H24O7 on the basis of HR-ESI-MS ([M+H]
+ at m/z 389.1552). The 
13C NMR spectral data of compound 11 were almost the same as those of compound 13 
except for the additional signal of one methoxy group. Based on the evidence above, 
compound 13 was determined as (+)-medioresinol.17 
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Figure 16. 1H –NMR and 13C –NMR spectra of compound 9 
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Figure 17. 1H –NMR and 13C –NMR spectra of compound 10 
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Figure 18. 1H –NMR and 13C –NMR spectra of compound 11 
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Figure 19. 1H –NMR and 13C –NMR spectra of compound 12 
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Figure 20. 1H –NMR and 13C –NMR spectra of compound 13 
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Table 1. 13C-NMR spectral data of lignans isolated from C.chinensis 
 
Carbon 
(-)-
asarinin 
4-
hydroxy 
sesamin 
(+)-
pinoresinol 
(+)-
epipinoresinol 
(+)-
medioresinol 
9 10 11 12 13 
δC
a, b δC
a, b δC
a, b δC
a, b δC
a, b 
1 50.1 135.4 133.2 53.7 132.3 
2 82.0 119.2 111.0 86.9 104.9 
3 87.6 108.0 147.8 
 
149.3 
4 70.9 148.1 148.8 70.2 137.4 
5 54.6 147.2 116.4 49.3 149.3 
6 87.6 106.3 119.7 81.3 104.9 
7 
 
83.3 86.4 
 
86.6 
8 69.6 62.1 54.8 68.7 55.0 
9 
 
101.7 71.9 
 
72.1 
1' 132.1 136.1 133.2 132.3 133.2 
2' 106.4 120.0 111.0 110.3 111.0 
3' 146.5 108.2 147.8 147.4 147.8 
4' 147.6 148.1 148.8 145.2 148.8 
5' 108.1 147.3 116.4 115.1 116.4 
6' 118.6 107.0 119.7 118.5 119.7 
7' 
 
88.1 86.4 
 
86.4 
8' 69.6 53.1 54.8 
 
54.7 
9' 
 
72.3 71.9 
 
71.9 
1'' 134.8 
  
129.6 
 
2'' 106.5 
  
109.8 
 
3'' 147.9 
  
147.2 
 
4'' 147.2 
  
145.9 
 
5'' 108.1 
  
115.1 
 
6'' 119.6 
  
117.8 
 
OMe 
  
56.0 55.5 56.0, 56.0 
OCH2O 101.0 101.1 
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1.1.14. Compound 14   
Compound 14 was obtained as yellow amorphous power. The molecular formula was 
established to be C15H10O6 on the basis of HR-ESI-MS ([M+H]
+ at m/z 287.0551). The 
1H-NMR spectrum obtained in DMSO an AA'BB' system constituted by two two-proton 
doublets (J = 8.8 Hz) at δ 8.03 and 6.86 typical of a para-substituted B ring of a flavonoid. 
Two further coupled doublets (J = 1.5 Hz) at δ 6.339 and 6.138 indicated the presence of 
the meta-related H-6 and H-8 C ring protons. The 13C NMR spectrum showed 15 signals, 
including 5 carbons attached with hydroxyl group and another carbon attached with 
oxygen. The chemical shifts of carbons in the literature were compared with those 
spectral data. As a result, compound 14 was identified as kaempferol.19 
 
1.1.15. Compound 15  
Compound 15 was obtained as yellow amorphous power. The molecular formula was 
established to be C15H10O7 on the basis of HR-ESI-MS ([M+H]
+ at m/z 304.0531). The 
13C NMR spectral data of compound 14 were almost the same as those of compound 15 
except for the additional signal of one methoxy group. Based on the evidence above, 
compound 15 was determined as quercetin.13 
 
1.1.16. Compound 16  
Compound 16 was obtained as yellow amorphous power. The molecular formula was 
established to be C16H12O7 on the basis of HR-ESI-MS ([M+HCOO]
- at m/z 361.0549). 
The 13C NMR spectral data of compound 14 were almost the same as those of compound 
16 except for the additional signal of one hydroxyl group. Based on the evidence above, 
compound 16 was determined as isorhamnetin.20 
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Figure 21. 1H –NMR and 13C –NMR spectra of compound 14 
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Figure 22. 1H –NMR and 13C –NMR spectra of compound 15 
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Figure 23. 1H –NMR and 13C –NMR spectra of compound 16 
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6-1-17. Compound 17  
Compound 17 was obtained as yellow amorphous power. The molecular formula was 
established to be C21H20O12 on the basis of HR-ESI-MS ([M+Na]
+ at m/z 487.0847). The 
1H-NMR spectrum showed 2 proton signals of A ring at δ 6.41 (1H, d, J = 1.8 Hz, H-8), 
6.20 (1H, d, J = 2 Hz, H-6) and 3 proton signals of a B ring at δ 7.53 (1H, d, J = 1.9 Hz, 
H-6′), 7.67 (1H, dd, J = 8.4, 2.5 Hz, H-5′) and 6.82 (1H, d, J = 8.5 Hz, H-2′). Therefore, 
the aglycone of compound 17 was elucidated to quercetin. The coupling constants (J), 
signal splitting patterns and chemical shifts in the proton and carbon signals of the sugar 
moieties suggested that the sugars were galactose. The 13C NMR spectrum showed δ 
103.939, 75.914, 73.232, 71.266, 67.988 and 60.222, which confirmed that the sugar part 
is galactose, corresponded with the signals from literature19 With the observed spectra 
data above, the structure of compound 17 was identified as quercetin 3-O-β-D-
galactopyranoside (hyperoside).19 
 
1.1.18. Compound 18  
Compound 18 was obtained as yellow amorphous power. The molecular formula was 
established to be C27H30O16 on the basis of HR-ESI-MS ([M+H]
+ at m/z 611.1609). The 
13C NMR spectral data of compound 17 were almost the same as those of compound 18 
except for the additional signal of sugar moiety. The signal of sugar moiety showed the 
methyl group, which confirmed that the sugar part is rutinose. Based on the evidence 
above, compound 18 was determined as Rutin.21 
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Figure 24. 1H –NMR and 13C –NMR spectra of compound 17 
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Figure 25. 1H –NMR and 13C –NMR spectra of compound 18 
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 Figure 26. Structures of the isolated compounds from C. chinensis 
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2. Anti-inflammatory activities of fraction and the compounds from 
C.chinensis 
BV-2 microglial cells were used as the screening tool in the process of searching for 
the anti-inflammatory activities in C.chinensis. The CHCl3, EtOAc and n-BuOH fractions 
of C.chinensis were evaluated for their ability to inhibit NO, the neurotoxic factor, against 
the LPS-stimulated BV-2 microglial cells. Isolated compounds 1 - 18 were also tested the 
anti-inflammatory activities. Cell viability was measured by MTT assay.  
As a result, the EtOAc fraction of C.chinensis inhibited LPS-induced NO production 
in BV-2 microglial cells. Among the isolated compounds, kaempferol (14), quercetin (15), 
and isorhamnetin (16) from the EtOAc fraction showed significant anti-inflammatory 
activity. Therefore, it can be deduced that these three compounds contributed the NO 
inhibition in the EtOAc fraction of C.chinensis. 
Compounds 14, 15 and 16 showed significant NO inhibitory effect with the IC50 
values of 19.23, 30.43 and 30.31 µM, respectively, which displayed more potent activity 
than L-NMMA, a well-known NO inhibitor with the IC50 value of 38.17 µM (Table 2). 
The entire compounds showed no cytotoxicity at the concentrations up to 50 µM. In this 
study, 5-hydroxy-6-methyl-2H-pyran-2-one (1), one of new compound, did not showed 
inhibitory effect of NO production. 
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Table 2. Inhibitory effect on NO production of compounds 1 - 18 in LPS-activated BV-2 cells 
Compounds IC50
a (µM) Cell viabilityb (%) 
NEW (1) > 500 79.4 ± 3.3 
Methyl paraben (2) > 500 78.0 ± 2.9 
p-Hydroxycinnamate (3) 63.31 77.1 ± 4.3 
p-Coumaric acid (4) > 500 79.1 ± 2.6 
Ferulic acid (5) > 500 77.7 ± 3.6 
Chlorogenic acid (6) > 500 82.4 ± 1.7 
β-Sitosterol (7) 165.6 81.1 ± 3.1 
Daucosterol (8) > 500 77.5 ± 0.6 
(-)-Asarinin (9) > 500 67.4 ± 3.9 
4-Hydroxysesamin (10) 140.3 65.0 ± 0.2 
(+)-Pinoresinol (11) 72.34 75.1 ± 2.9 
(+)-Epipinoresinol (12) 91.26 74.3 ± 3.0 
(+)-Medioresinol (13) 80.95 83.2 ± 2.0 
Kaempferol (14) 19.23 81.1 ± 3.2 
Quercetin (15) 30.43 78.5 ± 4.1 
Isorhamnetin(16) 30.31 82.3 ± 3.2 
Hyperoside(17) > 500 64.6 ± 1.9 
Rutin (18) > 500 76.1 ± 1.2 
L-NMMA
c
 38.17 84.5 ± 2.7 
a IC50 value of each compound was defined as the concentration (µM) that caused 50% inhibition 
of NO production in LPS-activated BV-2 cells. 
b Cell viability after treatment with 50 µM of each extract was expressed as a percentage (%) of 
the LPS only treatment group. The results are averages of three independent experiments, and the 
data are expressed as mean ± SD. 
c L-NMMA as a positive control. 
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3. Anaylsis of C.chinensis with HPLC-DAD 
Various HPLC columns, Shiseido C18 (250×4.6 mm id, 5 μm), Agilent zorbax SB- C18 
(5 μm; 250 × 4.6 mm, 5 μm) and YMC Hydrosphere C18 (250 × 4.6mm id, 5 μm) 
columns, were applied to analyze the tested samples. The preferred chromatographic 
separation was achieved using Shiseido C18 column. Various mixtures of water and 
MeCN in combination with several acids including phosphoric acid, acetic acid and 
formic acid were tested as a mobile phase to enhance the resolution about high polarity 
compounds. 22 
In this study, the addition of 0.1% phosphoric acid in water increased the resolution of 
the peaks, whereas the addition of other acids resulted in unsatisfying resolution and peak 
broadening. The wavelength was set at 230 nm, and the mobile flow rate was at 0.5 
mL/min (Table. 3). The presence of the five compounds in the extract was confirmed by 
comparing the retention times and UV spectra with those of each standard compounds. 
The retention times of chlorogenic acid (6), (+)-pinoresinol (11), kaempferol (14), 
quercetin (15), and hyperoside (17) were 12.02 min, 55.98 min, 70.10 min, 54.87 min, 
and 26.29 min, respectively. 
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Table. 3 HPLC-DAD conditions 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC conditions 
Instrument 
parameter 
Agilent 1290 UPLC system 
Column 
Shiseido hydrosphere C18 
(4.6 × 150 ㎜, 5 ㎛) 
Mobile 
phase 
Time 0.1% Phosphoric acid Acetonitrile 
0 85 15 
45 70 30 
66 63.8 36.2 
80 51.8 48.2 
Running 
time 
80 min 
Flow rate 0.500 mL/min 
Injection 
volume 
5 μL 
Detection UV 230 nm 
58 
 
 
 
Figure 27. HPLC-DAD chromatograms of 
(a) C.chinensis extract (50 μg/ml) and (b) standard mixture 
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3.1. Method validation 
The HPLC-DAD method for the determination of five compounds in C. chinensis 
extract was validated in terms of specificity, linearity, precision and accuracy. Standard 
stock solutions of chlorogenic acid (6), (+)-pinoresionl (11), kaempferol (14), quercetin 
(15), and hyperoside (17) were diluted to produce a test range from 0.4 – 4.0 mg/ml. The 
peaks of each isolated compounds were confirmed by comparison of their UV spectra 
with those of standard compounds. The calibration curve showed a highly linear 
regression of the peak areas versus concentrations of each standard (R2 = 0.999 for 
compound 1, R2 = 0.999 for compound 2, R2= 0.999 for compound 3, R2 = 0.999 for 
compound 4 and R2 = 0.999 for compound 5). Limit of detection (LOD) and limit of 
quantitation (LOQ) were defined as the signal-to-noise ratio (S/N) of 3.3 and 10, 
respectively.22 The LODs were between 2.95 and 40.28 ng. The LOQs were between 8.95 
and 122.05 ng, which showed satisfying sensitivity under this chromatographic condition. 
The precision was preceded by the intraday and interday variability for each compound. 
The intraday variability was assayed at three concentrations on the same day and interday 
variability at three concentrations on three different days (1, 3, and 5 days). The accuracy 
was evaluated using the recovery test. The recoveries of five compounds with RSD less 
than 1% were within 98.49 – 104.43%. This method was developed and validated to 
confirm the content of 6 compounds, chlorogenic acid (6), (+)-pinoresinol (11), 
kaempferol (14), quercetin (15), and hyperoside (17), in extracts. The contents were 0.549, 
0.746, 3.285, 0.640 and 10.910%, respectively, where the content can be ranked as 
hyperoside (17) > kaempferol (14) > (+)-pinoresionl (11) > chlorogenic acid (6) > 
quercetin (15). 
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Table 4. Linearity of the calibration curves 
Compound Regression equation
a
 
Correlation 
coefficient 
(R
2
) 
LOD LOQ 
(μg) (μg) 
Chlorogenic acid y = 2979.62x + 28.86 0.9999 0.0037 0.0113 
Hyperoside y = 2600.00x + 365.52 0.9999 0.0403 0.1221 
Quercetin y = 5691.86x + 46.48 0.9999 0.0032 0.0096 
(+)-Pinoresinol y = 4259.15x+ 37.34 0.9999 0.0030 0.0090 
Kaempferol y = 5906.76x + 133.38 0.9999 0.0109 0.0330 
ay : peak area, x : concentration (mg/ml) 
 
Table 5. Precision and accuracy 
compound 
Precision 
Accuracy 
Inter-day Intra-day 
Amount RSD Amount RSD 
Sam.:Std. 
Spiked 
amount 
Accuracy RSD 
(μg) (%)a (μg) (%)a (μg) (%) (%) a 
Chlorogenic 
acid 
0.59795 0.4 0.59694 0.132 1:2 1.0216 100.96 0.06 
0.47732 0.371 0.47885 0.06 1:1 0.9348 98.490 0.10 
0.24632 0.162 0.24697 0.211 2:1 1.0840 100.87 0.08 
Hyperoside 
6.00592 0.323 6.04944 0.115 1:2 14.6485 103.29 0.05 
4.79932 0.371 4.85565 0.071 1:1 15.1183 101.40 0.29 
2.47045 0.151 2.49173 0.149 2:1 13.8311 102.80 0.18 
Quercetin 
0.59561 0.694 0.59648 0.231 1:2 1.1257 104.21 0.29 
0.4781 0.301 0.47516 0.547 1:1 1.0256 98.580 0.45 
0.24522 0.397 0.24416 0.153 2:1 1.1335 101.19 0.97 
(+)-
Pinoresinol 
0.59579 1.085 0.60214 0.183 1:2 1.1996 103.45 0.05 
0.47952 0.807 0.48179 0.758 1:1 1.1828 103.20 0.79 
0.24468 0.029 0.24663 0.088 2:1 1.1999 102.29 0.21 
Kaempferol 
1.48633 0.555 1.5009 0.005 1:2 4.0711 102.71 0.03 
1.19272 0.288 1.19944 0.064 1:1 4.4749 104.43 0.44 
0.61812 0.572 0.61675 0.147 2:1 3.7335 102.50 0.14 
aR.S.D(%)=(SD of amount detected/mean of amount detected)×100 
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Table 6. Quantitative anaylsis 
Compounds Content (%) RSD (%) 
Chlorogenic acid 0.5492 0.531 
Hyperoside 10.909 0.553 
Quercetin 0.634 2.995 
(+)-Pinoresinol 0.746 2.132 
Kaempferol 3.285 0.344 
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DISCUSSIONS 
The discovery of NO as an intercellular messenger or neurotransmitter opened a novel 
era for identifying the important mechanisms underlying physiological and 
pathophysiological events in innervated organs and tissues.23 Inability to generate enough 
NO in the corpus cavernosum causes the main impaired sexual function of male erectile 
dysfunction. Therefore, regulating appropriate level of NO is an important factor to 
maintaining sexual function for men. Oja, a traditional Chinese herbal medicine 
composing five seeds of Cuscuta chinensis, Lyceum chinensis, Schisandra chiensis, 
Torillis japonica and Rubus coreanus fruit, is commonly used for enhancing sexual 
function for men and protecting the kidney. In Oja, only C. chinensis has not been studied 
well for its composition and the method for quality control compared to other seeds.  
Therefore, in the present study, we successfully isolated eighteen compounds from C. 
chinensis and tested their inhibitory effects on NO production in LPS-stimulated BV2 
cells. Then, we developed and validated a new HPLC-DAD method to simultaneously 
determine five major compounds in C.chinensis. 
As a result, one new α-pyrone, 5-hydroxy-6-methyl-2H-phran-2-one methyl-2H-phran-
2-one (1), along with seven phenolic derivatives (2 - 8), five lignans (9 - 13), five 
flavonoids (14 - 18) were isolated from C. chinensis by various chromatographic 
techniques. Among the isolated compounds 14, 15 and 16 showed a significant inhibitory 
effect of NO production with the IC50 values of 19.23, 30.43 and 30.31 µM, respectively. 
As a result, compounds 14, 15, and 16, the NO inhibitory compounds, are thought to be 
closely related to the efficacy of Oja as enhancing sexual function.  
Since C. chinensis cannot photosynthesis itself, it relies on other plant. Depending on 
where it parasites, its chemical composition and efficacy can be significantly different.   
63 
Therefore, study on chemical compositions and efficacy among various origins of 
C.chinensis must be carried on in order to utilize proposed HPLC-DAD validation 
method as a quality control method for C.chinensis. 
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CONCLUSIONS 
1. Eight phenolic derivatives (1 - 8), five lignans (9 - 13), five flavonoids (14 - 18) were 
isolated from the CHCl3, EtOAc and n-BuOH fractions of Cuscuta chinensis by 
chromatographic techniques. 
2. Compound 1 was reported for the first time from the nature, which was designated to 
5-hydroxy-6-methyl-2H-pyran-2-one. 
3. The EtOAc fractions of C. chinensis inhibited lipopolysaccharide (LPS)-induced NO 
production in BV-2 microglial cells. 
4. Among these isolated compounds from EtOAc, compounds 14, 15 and 16 suppressed 
LPS-induced NO production in BV-2 microglial cells. 
5. A novel selective HPLC method was developed and validated to confirm the content of 
5 compounds, chlorogenic acid (6), (+)-pinoresinol (11), kaempferol (14), quercetin (15), 
and hyperoside (18) in C. chinensis extracts. The contents were 0.549, 0.746, 3.285, 
0.640 and 10.910%, respectively, where the content can be ranked as hyperoside (18) > 
kaempferol (14) > (+)-pinoresionl (11) > chlorogenic acid (6) > quercetin (15). 
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ABSTRACT  
Isolation and simultaneous determination of 
bioactive components from Cuscuta chinensis 
 
YoonJae Kim 
Dept. of Pharmacy 
The Graduate School 
Yonsei University 
 
Increased in life span of populations in the world has led to an elevated frequency of 
neurodegenerative diseases. A gradual and progressive neuronal cell death occurs as a 
consequence of increased nitrosative stress and an uncontrolled neuroinflammatory 
response. This process involves the activation of microglial cells and leads to the 
initiation and progression of various neurodegenerative diseases. Activation of microglia 
and consequent release of different proinflammatory factors such as interleukin-1 beta, 
IL-6, tumor necrosis factor-alpha, nitric oxide, reactive oxygen species , inducible nitric 
oxide synthase and cyclooxygenase-2 contribute to neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s disease by increasing inflammations in the brain. 
The seeds of Cuscuta chinensis (Conbolvulaceas) are commonly used as a medicinal 
plant for the treatment of the aching and weakness of the loins and knees as well as 
tonifying the defects of liver and kidney. It was also used for the treatment of diarrhea 
caused to hypofunction of kidney and spleen. To the best of the knowledge, lignans, 
flavonoids and other phenolic components are known to be its chemical constituents. 
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In this study, one new α-pyrone, 5-hydroxy-6-methyl-2H-phran-2-one methyl-2H-
phran-2-one (1), along with seventeen known compounds were isolated from the CHCl3, 
EtOAc and n-BuOH fractions of C. chinensis by various chromatographic techniques. 
The known compounds were identified as methyl paraben (2), p-hydroxycinnamate (3), 
p-coumaric acid (4), ferulic acid (5), chlorogenic acid (6), β-sitosterol (7), daucosterol (8), 
(-)-asarinin (9), 4-hydroxysesamin (10), (+)-pinoresinol (11), (+)-epipinoresinol (12), (+)-
medioresinol (13), kaempferol (14), quercetin (15), isorhamnetin (16), hyperoside (17), 
and rutin (18) by using various spectroscopic data and comparing them with literatures. 
Based on the previous study of nitric oxide inhibitory activity of Cuscuta chinensis 
extract in BV-2 microglia, these isolated compounds were evaluated for anti-
neuroinflammatory activities against the lipopolysaccharide-stimulated BV-2 microglial 
cells. The EtOAc fraction of C.chinensis inhibited lipopolysaccharide-induced nitric 
oxide production in BV-2 microglial cells. Among the isolated compounds from EtOAc 
fraction, compound 14, 15 and 16 showed significant anti-inflammatory activity. 
In the present study, a new HPLC-DAD method for simultaneous determination of 
isolated compounds that has been majorly detected in EtOAc fraction, namely 
chlorogenic acid (6), (+)-pinoresinol (11), kaempferol (14), quercetin (15), and 
hyperoside (17) was developed and validated. The method was validated in terms of 
specificity, linearity (R2 > 0.9999), precision [relative standard deviation < 0.97%] and 
accuracy (98.5–107.3%). The limit of detection and limit of quantification were < 8.96 
and 122.05 ng for all analytes, respectively. The validated method was successfully 
applied to quantify five compounds in C.chinensis. 
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